MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Iovance Biotherapeutics ROCE Ratio 2011-2026 | IOVA
Annual ROCE Ratio Iovance Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -52.06 | -50.16 | -68.74 | -69.67 | -49.8 | -36.71 | -67.7 | -27.5 | -63.84 | -32.13 | -26.78 | -26.85 | -128.61 | 71.85 | 164.76 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 164.76 | -128.61 | -30.93 |
Quarterly ROCE Ratio Iovance Biotherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -51.36 | -49.38 | -46.47 | -36.87 | -52.42 | -57.76 | -62.52 | -47.04 | -68.55 | -74.52 | -79.16 | -57.31 | -68.59 | -58.37 | -47.55 | -32.43 | -40.69 | -37.67 | -36.31 | -27.1 | -43.99 | -52.62 | -60.12 | -46.39 | -53.91 | -44.54 | -34.85 | -20.01 | -35.36 | -43.21 | -52.69 | -45.92 | -57.29 | -53.3 | -44.12 | -22.6 | -29.94 | -25.92 | -25.09 | -18.63 | -24.88 | -23.78 | -22.3 | -15.99 | -69.44 | -116.64 | -117.78 | -63.3 | -48.92 | 18.91 | 39.3 | 56.63 | 102.12 | 133.23 | 201.32 | 133.27 | 45.49 | 82.63 | 5.15 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 201.32 | -117.78 | -25.89 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.88 | 3.89 % | $ 9.34 B |  Australia |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
63.56 | $ 323.44 | -2.98 % | $ 42.4 B | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-164.32 | $ 7.93 | 6.81 % | $ 78.4 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 21.93 | 1.15 % | $ 1.03 B | USA |
 |
Burford Capital Limited
BUR
|
14.24 | $ 4.71 | -0.63 % | $ 766 M | Britain |
 |
Cabaletta Bio
CABA
|
-153.72 | $ 3.54 | 4.12 % | $ 356 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 101.62 | 2.16 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.07 | -3.15 % | $ 5.05 M | Israel |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
545.12 | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
72.06 | $ 1.38 | -10.97 % | $ 355 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
211.07 | $ 4.22 | -0.59 % | $ 451 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 23.83 | -3.05 % | $ 3.03 B | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.54 | 3.02 % | $ 410 M | Britain |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-75.78 | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
156.13 | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
-54.51 | $ 33.61 | -0.77 % | $ 2.23 B | USA |
 |
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-353.49 | $ 2.72 | -1.09 % | $ 1.21 M | USA |
 |
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B | Britain |